Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16832025,release rate,A sustained-release fluocinolone acetonide intravitreal implant with a release rate of either 0.5 microg/d (n = 16) or 0.1 microg/d (n = 16) was implanted into the vitreous cavity of the right eye in albino rabbits after a subcutaneous injection of tuberculin antigen.,Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832025/),[μg] / [d],0.5,7348,DB00591,Fluocinolone Acetonide
,16832025,release rate,A sustained-release fluocinolone acetonide intravitreal implant with a release rate of either 0.5 microg/d (n = 16) or 0.1 microg/d (n = 16) was implanted into the vitreous cavity of the right eye in albino rabbits after a subcutaneous injection of tuberculin antigen.,Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832025/),[μg] / [d],0.1,7349,DB00591,Fluocinolone Acetonide
,17883883,oral bioavailability,Its oral bioavailability is poor (6.7%).,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),%,6.7,29050,DB00591,Fluocinolone Acetonide
,17883883,Plasma half-life,Plasma half-life is estimated to be 3.9 to 4.6 hours.,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,3.9 to 4.6,29051,DB00591,Fluocinolone Acetonide
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),l,96,29052,DB00591,Fluocinolone Acetonide
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,1.6,29053,DB00591,Fluocinolone Acetonide
greater,25562126,elimination half lives,The elimination half lives in the tissues for which it was measurable were greater than 83 days.,Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562126/),d,83,83634,DB00591,Fluocinolone Acetonide
,11835202,particle size,The average HFA flunisolide particle size is 1.2 microm compared with 3.8 microm for the CFC formulation.,Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835202/),μm,1.2,85799,DB00591,Fluocinolone Acetonide
,11835202,particle size,The average HFA flunisolide particle size is 1.2 microm compared with 3.8 microm for the CFC formulation.,Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835202/),μm,3.8,85800,DB00591,Fluocinolone Acetonide
,11835202,Area under the curve up to the time corresponding to the last measurable concentration (AUC(0)(-)(tlast)),"Area under the curve up to the time corresponding to the last measurable concentration (AUC(0)(-)(tlast)) was similar for the CFC and HFA flunisolide, plus spacer groups (4.4 +/- 1.6 ng x h/mL and 5.0+/- 4.2 ng x h/mL, respectively); however, AUC(0)(-)(tlast) for the HFA flunisolide without spacer group was comparatively lower than for the CFC group (3.5 +/- 1.6 ng x h/mL).",Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835202/),[h·ng] / [ml],4.4,85801,DB00591,Fluocinolone Acetonide
,11835202,Area under the curve up to the time corresponding to the last measurable concentration (AUC(0)(-)(tlast)),"Area under the curve up to the time corresponding to the last measurable concentration (AUC(0)(-)(tlast)) was similar for the CFC and HFA flunisolide, plus spacer groups (4.4 +/- 1.6 ng x h/mL and 5.0+/- 4.2 ng x h/mL, respectively); however, AUC(0)(-)(tlast) for the HFA flunisolide without spacer group was comparatively lower than for the CFC group (3.5 +/- 1.6 ng x h/mL).",Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835202/),[h·ng] / [ml],5.0,85802,DB00591,Fluocinolone Acetonide
,11835202,AUC(0)(-)(tlast),"Area under the curve up to the time corresponding to the last measurable concentration (AUC(0)(-)(tlast)) was similar for the CFC and HFA flunisolide, plus spacer groups (4.4 +/- 1.6 ng x h/mL and 5.0+/- 4.2 ng x h/mL, respectively); however, AUC(0)(-)(tlast) for the HFA flunisolide without spacer group was comparatively lower than for the CFC group (3.5 +/- 1.6 ng x h/mL).",Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835202/),[h·ng] / [ml],3.5,85803,DB00591,Fluocinolone Acetonide
,38078,plasma t 1/2,"Flunisolide (6 alpha-fluoro-11 beta, 16 alpha, 17 alpha, 21-tetrahydroxypregna-1,4-diene-3,20-dione 16,17-acetonide) administered as a single iv or oral dose to rats, mice, dogs, rhesus monkeys, and cynomolgus monkeys had a plasma t 1/2 of 1-3.5 hr and was eliminated mainly via the bile.","Disposition of flunisolide in the rat, mouse, dog, rhesus monkey, and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38078/),h,1-3.5,120478,DB00591,Fluocinolone Acetonide
,38078,apparent volume of distribution,The apparent volume of distribution of flunisolide in these five species was 3.0-8.0 liters/kg.,"Disposition of flunisolide in the rat, mouse, dog, rhesus monkey, and cynomolgus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38078/),[l] / [kg],3.0-8.0,120479,DB00591,Fluocinolone Acetonide
,12476540,elimination half-life,The elimination half-life of flunisolide ranged from 0.95 to 1.34 hours.,Multiple-dose proportionality study of flunisolide hydrofluoroalkane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476540/),h,0.95 to 1.34,159641,DB00591,Fluocinolone Acetonide
,7357797,systemic availability,"In a separate study in 12 normal subjects, flunisolide in plasma was quantitated by radioimmunoassay (RIA); average systemic availability was 20%.",Flunisolide metabolism and dynamics of a metabolite. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357797/),%,20,165309,DB00591,Fluocinolone Acetonide
,10831007,oral bioavailability,"Flunisolide is a corticosteroid with low oral bioavailability (6.7%), which was found to be lower than previously reported.",Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10831007/),%,6.7,170323,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],11-18,176138,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],75-146,176139,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],42-87,176140,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],224-489,176141,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],0.21-1.1,176142,DB00591,Fluocinolone Acetonide
,15279731,Concentrations,"Concentrations of FA were generally higher in the vitreous (11-18 and 75-146 ng/g) and retina (42-87 and 224-489 ng/g) than in the aqueous humor (0.21-1.1 and 2.6-13.0 ng/g) for the 0.5- and 2-mg implants, respectively.",Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15279731/),[ng] / [g],2.6-13.0,176143,DB00591,Fluocinolone Acetonide
,11006254,drug release rates,"The drug release rates for the 2-mg device, 1.9 +/- 0.25 microg/d, and for the 15-mg device, 2.2 +/- 0.6 microg/d, remained linear over the 6-month and 45-day testing period, respectively.",Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11006254/),[μg] / [d],1.9,184115,DB00591,Fluocinolone Acetonide
,11006254,drug release rates,"The drug release rates for the 2-mg device, 1.9 +/- 0.25 microg/d, and for the 15-mg device, 2.2 +/- 0.6 microg/d, remained linear over the 6-month and 45-day testing period, respectively.",Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11006254/),[μg] / [d],2.2,184116,DB00591,Fluocinolone Acetonide
,11006254,life span,"Based on the device release rates, the predicted life span of the 2- and 15-mg devices are 2.7 and 18.6 years, respectively.",Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11006254/),years,2.7,184117,DB00591,Fluocinolone Acetonide
,11006254,life span,"Based on the device release rates, the predicted life span of the 2- and 15-mg devices are 2.7 and 18.6 years, respectively.",Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11006254/),years,18.6,184118,DB00591,Fluocinolone Acetonide
,11681651,Lung deposition,Lung deposition expressed as percentage ex-device (delivered) dose averaged 68.3% for HFA pMDI plus spacer and 19.7% for CFC pMDI.,Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11681651/),%,68.3,249639,DB00591,Fluocinolone Acetonide
,11681651,Lung deposition,Lung deposition expressed as percentage ex-device (delivered) dose averaged 68.3% for HFA pMDI plus spacer and 19.7% for CFC pMDI.,Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11681651/),%,19.7,249640,DB00591,Fluocinolone Acetonide
,9505980,Maximum concentration,Maximum concentration levels of 3 to 9 ng/mL of flunisolide were observed after 0.2 to 0.3 hours for all of the investigated doses.,Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505980/),[ng] / [ml],3 to 9,254834,DB00591,Fluocinolone Acetonide
,9505980,terminal half-life,The terminal half-life ranged from 1.3 to 1.7 hours.,Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505980/),h,1.3 to 1.7,254835,DB00591,Fluocinolone Acetonide
